• Q-VD-OPh in Rab14–Parkin Mitophagy Assays

  2026-09-15

  Q-VD-OPh helps researchers separate caspase-dependent cell death from Rab14–Parkin mitophagy, improving interpretation of mitochondrial quality-control experiments. Its cell and brain permeability also supports apoptosis research, neurodegeneration models, and post-cryopreservation viability studies.

• Cy5 Hydrazide: Making Carbonyls Translationally Visible

  2026-09-15

  Carbonyl chemistry offers a practical bridge between nanoparticle formulation, oxidative biology, and translational quality control. This article examines how Cy5 hydrazide can help researchers connect particle behavior with molecular evidence while maintaining realistic boundaries around solvent compatibility, food-grade claims, and clinical readiness.

• PD 0332991 (Palbociclib HCl): CDK4/6 Guide

  2026-09-14

  PD 0332991, also called Palbociclib HCl, is an orally bioavailable CDK4/6 inhibitor that suppresses Rb-positive tumor-cell proliferation through G1 arrest. Its reported biochemical potency, cell-cycle effects, xenograft activity, and handling parameters support controlled research use rather than direct clinical or diagnostic use.

• AT-406 Workflows for Apoptosis Research

  2026-09-14

  AT-406 (SM-406) connects multi-IAP antagonism with practical apoptosis readouts, chemotherapy-sensitization studies, and translational xenograft workflows. This guide emphasizes dosing design, mechanistic time courses, assay controls, and troubleshooting for reproducible cancer research.

• REV1–DHX36 Control of G-Quadruplex Replication

  2026-09-13

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, fork progression, and suppression of single-stranded DNA gaps. The findings establish a two-tier model for G4 tolerance and clarify how REV1 loss amplifies replication stress and ATM/ATR signaling.

• PPM-18 Workflows for NF-κB/iNOS Research

  2026-09-12

  PPM-18 enables pathway-focused studies that separate NF-κB-driven iNOS expression from direct nitric oxide synthase enzyme inhibition. This article provides practical macrophage, inflammation, sepsis, and exploratory bone-remodeling workflows, with controls and troubleshooting guidance for reliable interpretation.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-11

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It produces blunt-ended products and should not be selected when a PCR workflow requires 3′-A overhangs or sticky ends.

• From FLASH-RT to Cell-Death Decisions

  2026-09-11

  A translational framework for using Annexin V-FITC/7-AAD dual-parameter analysis to connect BRD4-targeted FLASH-radiotherapy mechanisms with interpretable apoptosis, necrosis, viability, and cytotoxicity readouts.

• Digoxin, HIF-1α, and Thyroid Eye Disease

  2026-09-10

  A 2026 pre-proof study identifies HIF-1α as a mechanistic link between hypoxia, inflammation, fibrosis, STAT3 activation, and GSDME-mediated pyroptosis in thyroid eye disease. In primary orbital fibroblast models, low-nanomolar Digoxin reversed these responses, supporting HIF-1α inhibition as a potential strategy for mechanism-directed TED research while leaving important questions about specificity and in vivo translation.

• Batimastat (BB-94) in MMP and BDNF Assays

  2026-09-10

  Batimastat (BB-94) provides a practical way to test how extracellular MMP activity influences tumor invasion, angiogenesis, and localized BDNF processing. This guide connects a broad-spectrum hydroxamate inhibitor with cancer workflows and a carefully bounded neuromuscular-junction assay strategy.

• Isorhamnetin and PI3K/Akt in Oocyte Maturation

  2026-09-09

  The reference study shows that isorhamnetin improves porcine oocyte maturation while reducing oxidative stress, apoptosis, mitochondrial dysfunction, and endoplasmic reticulum stress. Its main contribution is linking these protective effects to activation of the PI3K/Akt pathway, providing a mechanism-focused framework for reproductive biology experiments.

• PDHA1 Succinylation and α-KGA in Cholangiocarcinoma

  2026-09-09

  A 2025 Nature Communications study identifies PDHA1 K83 succinylation as a metabolic control point that increases alpha-ketoglutarate accumulation in the cholangiocarcinoma microenvironment. The resulting α-KGA–OXGR1–MAPK axis suppresses macrophage MHC-II antigen presentation, while pharmacologic inhibition of succinylation improves responses to gemcitabine and cisplatin in the reported experimental systems.

• Bay 11-7821: Mapping Pathogen-Driven NF-κB

  2026-09-09

  Bay 11-7821, also known as BAY 11-7082, provides a practical way to test whether pathogen-triggered monocyte inflammation depends on the NF-κB branch downstream of TLR2/TLR4. This article translates CPSIT_0844 findings into assay-design decisions while distinguishing pathway validation from receptor-level attribution.

• Naftifine HCl: Research Workflows and Troubleshooting

  2026-09-08

  Naftifine HCl combines a defined sterol-biosynthesis mechanism with flexible DMSO- and ethanol-based preparation for reproducible antifungal research. This guide translates its use into practical susceptibility, cell-compatibility, and mechanism-focused workflows while using the WNT5a/GSK3/β-catenin study as a model for orthogonal assay design.

• Topotecan for Ovarian Cancer: Evidence and Limits

  2026-09-07

  The Cochrane review by Abudou and colleagues synthesized randomized evidence on adding Topotecan to platinum–taxane chemotherapy for ovarian cancer. Its central finding was that the combination did not establish a clear survival advantage, while treatment-related toxicity remained an important consideration for clinical interpretation and future study design.

8802 records 1/587 page Next 12345 下5页 Last page